US FDA expediting of generic approvals a mixed bag for India drug makers
newsdepo.com
The US drug regulator has cleared record number of abbreviated new drug applications (ANDAs) in 2017, as it aims to expand competition in generic drugs and there by reduce healthcare costs for US citizens.US FDA expediting of generic approvals a mixed bag for India drug makers
The US drug regulator has cleared record number of abbreviated new drug applications (ANDAs) in 2017, as it aims to expand competition in generic drugs and there by reduce healthcare costs for US citizens. Read more